ID: ALA345989

Max Phase: Preclinical

Molecular Formula: C22H19ClN2O4

Molecular Weight: 410.86

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(C)c(Cl)cc3nc2-1

Standard InChI:  InChI=1S/C22H19ClN2O4/c1-3-22(28)8-19(26)29-10-14-15(22)6-18-20-13(9-25(18)21(14)27)5-12-4-11(2)16(23)7-17(12)24-20/h4-7,28H,3,8-10H2,1-2H3

Standard InChI Key:  LZYXEYCPEDEDJP-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 410.86

Molecular Weight (Monoisotopic): 410.1033

AlogP: 3.43

#Rotatable Bonds: 1

Polar Surface Area: 81.42

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.81

CX Basic pKa: 2.36

CX LogP: 2.27

CX LogD: 2.27

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.49

Np Likeness Score: 0.57

References

1. Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, Harnett J, Pons D, Camara J, Bigg DC..  (1998)  Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.,  41  (27): [PMID:9876111] [10.1021/jm980400l]

2. Huang Q, Wang L, Lu W..  (2013)  Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.,  63  [PMID:23578545] [10.1016/j.ejmech.2013.01.058]

Source

Source(1):

• Scientific Literature